Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multi-center, single-arm, phase 2 trial

被引：0
|
作者：
Zhao, Wensi
Li, Jun
Li, Liping
Huang, Junping
Gong, Wei
Yu, Xiongjie
Le, Kefa
He, Linli
Han, Qi
Wang, Songlin
Tang, Ze
Li, Wenbin
Hua, Xianliang
Chen, Yongshun
机构：
[1] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China
[2] Cent Hosp Xiao Gan, Dept Oncol, Xiaogan, Peoples R China
[3] Xiantao First Peoples Hosp, Xiantao, Peoples R China
[4] Jianghan Oilfield Gen Hosp, Qianjiang, Peoples R China
[5] Hubei Univ Art & Sci, Dept Oncol, Xiang Yang Cent Hosp, Xiangyang, Peoples R China
[6] Peoples Hosp Shiyan, Shiyan, Peoples R China
[7] Peoples Hosp Yangxin, Dept Oncol, Yangxin, Peoples R China
[8] First Peoples Hosp Tianmen City, Hubei Technol Coll, Dept Abdominal & Pelv Med Oncol, Affiliated Hosp, Tianmen, Peoples R China
[9] Xianning Cent Hosp, Xianning, Peoples R China
[10] Zhongxiang Peoples Hosp, Zhongxiang, Peoples R China
[11] Huangshi Cent Hosp, Dept Oncol, Huangshi, Hubei, Peoples R China
[12] Qianjiang Cent Hosp, Dept Oncol, Qianjiang, Peoples R China
[13] Wuhan Univ, Dept Clin Oncol, Renmin Hosp, Wuhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
    Kuang, Chaoyuan
    Park, Yongseok
    Augustin, Ryan C.
    Lin, Yan
    Hartman, Douglas J.
    Seigh, Lindsey
    Pai, Reetesh K.
    Sun, Weijing
    Bahary, Nathan
    Ohr, James
    Rhee, John C.
    Marks, Stanley M.
    Beasley, H. Scott
    Shuai, Yongli
    Herman, James G.
    Zarour, Hassane M.
    Chu, Edward
    Lee, James J.
    Krishnamurthy, Anuradha
    CLINICAL EPIGENETICS, 2022, 14 (01)
  • [32] Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
    Chaoyuan Kuang
    Yongseok Park
    Ryan C. Augustin
    Yan Lin
    Douglas J. Hartman
    Lindsey Seigh
    Reetesh K. Pai
    Weijing Sun
    Nathan Bahary
    James Ohr
    John C. Rhee
    Stanley M. Marks
    H. Scott Beasley
    Yongli Shuai
    James G. Herman
    Hassane M. Zarour
    Edward Chu
    James J. Lee
    Anuradha Krishnamurthy
    Clinical Epigenetics, 2022, 14
  • [33] Capecotabome plus cetuximab as second-line chemotherapy in elderly patients with metastatic colorectal cancer: Results of a phase II study
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Petricola, F.
    Restuccia, M.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 86 - 86
  • [34] Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
    Yang, C.
    Huang, H.
    Zeng, X.
    Dai, H.
    Zhou, G.
    Wang, S.
    Hu, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S1148 - S1148
  • [35] MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
    Alexios Matikas
    John Souglakos
    Panagiotis Katsaounis
    Athanasios Kotsakis
    Panagiotis Kouroupakis
    Nikolaos Pantazopoulos
    Nikolaos Kentepozidis
    Adamantia Nikolaidi
    Ippokratis Messaritakis
    Ioanna Tzovara
    Dora Hatzidaki
    Efthymis Prinarakis
    Vassilis Georgoulias
    Targeted Oncology, 2019, 14 : 285 - 293
  • [36] MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
    Matikas, Alexios
    Souglakos, John
    Katsaounis, Panagiotis
    Kotsakis, Athanasios
    Kouroupakis, Panagiotis
    Pantazopoulos, Nikolaos
    Kentepozidis, Nikolaos
    Nikolaidi, Adamantia
    Messaritakis, Ippokratis
    Tzovara, Ioanna
    Hatzidaki, Dora
    Prinarakis, Efthymis
    Georgoulias, Vassilis
    TARGETED ONCOLOGY, 2019, 14 (03) : 285 - 293
  • [37] Toripalimab with Fruquintinib as the third-line treatment for refractory advanced metastatic colorectal cancer: Results of a single-arm, single-center, prospective, phase II clinical study.
    Ma, Shoucheng
    Chen, Rui
    Hou, Xiaoming
    Duan, Lin
    Li, Chunmei
    Yang, Tianning
    Ling, Xiaoling
    Zhao, Da
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15573 - E15573
  • [38] Efficacy and safety of second-line therapy by S-1 combined with Sintilimab and Anlotinib in pancreatic cancer patients with liver metastasis: A single-arm, phase II clinical trial.
    Du, Juan
    Qiu, Xin
    Lu, Changchang
    Sha, Huizi
    Zhu, Yahui
    Kong, Weiwei
    Li, Xing
    Qian, Xiaoping
    Liu, Baorui
    CANCER RESEARCH, 2022, 82 (12)
  • [39] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kimura, Kosei
    Iwamoto, Mitsuhiko
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
  • [40] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kosei Kimura
    Mitsuhiko Iwamoto
    Satoru Tanaka
    Daigo Yamamoto
    Katsuhide Yoshidome
    Hiroyuki Ogura
    Risa Terasawa
    Nobuki Matsunami
    Yuko Takahashi
    Toshikatsu Nitta
    Takashi Morimoto
    Hiroya Fujioka
    Kanako Kawaguchi
    Kazuhisa Uchiyama
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933
12345